See more : Newag S.A. (NWG.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Canopy Growth Corporation (CGC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Canopy Growth Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Santosh Fine Fab Limited (SANTOSHF.BO) Income Statement Analysis – Financial Results
- Zhejiang Jingxing Paper Joint Stock Co., Ltd. (002067.SZ) Income Statement Analysis – Financial Results
- Luboa Group, Inc. (LBAO) Income Statement Analysis – Financial Results
- LightPath Technologies, Inc. (LPTH) Income Statement Analysis – Financial Results
- UEKI Corporation (1867.T) Income Statement Analysis – Financial Results
Canopy Growth Corporation (CGC)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.canopygrowth.com
About Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 297.15M | 402.90M | 520.33M | 546.65M | 398.77M | 226.34M | 77.95M | 39.90M | 12.70M | 1.15M | 0.00 | 4.14K | 0.00 | 4.49K | 549.00 |
| Cost of Revenue | 216.26M | 507.04M | 713.38M | 479.69M | 430.46M | 137.41M | 3.76M | 2.26M | -6.29M | 731.31K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 80.88M | -104.14M | -193.05M | 66.96M | -31.68M | 88.93M | 74.19M | 37.63M | 18.99M | 414.35K | 0.00 | 4.14K | 0.00 | 4.49K | 549.00 |
| Gross Profit Ratio | 27.22% | -25.85% | -37.10% | 12.25% | -7.95% | 39.29% | 95.18% | 94.33% | 149.51% | 36.17% | 0.00% | 100.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 4.61M | 21.72M | 32.34M | 57.58M | 61.81M | 15.24M | 1.45M | 810.00K | 721.00K | 159.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 99.83M | 487.41M | 520.28M | 666.54M | 624.91M | 451.44M | 92.93M | 25.59M | 11.67M | 6.00M | 739.94K | 68.75K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 76.15M | 243.45M | 239.28M | 194.40M | 242.83M | 154.39M | 38.20M | 12.96M | 5.65M | 1.99M | 191.72K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 175.98M | 487.41M | 520.28M | 666.54M | 867.74M | 605.83M | 131.13M | 38.55M | 17.33M | 7.99M | 931.66K | 68.75K | 26.16K | 28.56K | 27.47K |
| Other Expenses | 129.01M | -21.72M | -32.34M | -57.58M | 63.62M | 21.51M | 20.49M | -585.00K | 2.26M | -966.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 309.60M | 487.41M | 520.28M | 666.54M | 993.17M | 642.58M | 153.07M | 45.43M | 20.30M | 8.15M | 931.66K | 68.75K | 26.16K | 28.56K | 27.47K |
| Cost & Expenses | 525.86M | 994.46M | 1.23B | 1.15B | 1.42B | 779.99M | 156.82M | 47.69M | 14.02M | 8.88M | 931.66K | 68.75K | 26.16K | 28.56K | 27.47K |
| Interest Income | 16.24M | 24.28M | 6.60M | 21.37M | 66.33M | 49.31M | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.76K | 4.49K | 549.00 |
| Interest Expense | 105.35M | 126.16M | 103.94M | 8.46M | 6.72M | 18.42M | 784.00K | 66.00K | 140.00K | 65.82K | 1.27K | 0.00 | 4.76K | 4.49K | 0.00 |
| Depreciation & Amortization | 53.18M | 80.03M | 114.42M | 127.12M | 125.01M | 46.92M | 20.49M | 6.06M | 2.26M | 362.90K | 4.19K | 0.00 | -4.76K | -4.49K | 0.00 |
| EBITDA | -312.83M | -2.88B | -121.15M | -1.50B | -1.31B | -631.83M | -29.80M | -692.00K | 938.00K | -6.96M | -925.99K | -64.61K | -26.16K | -24.07K | -26.92K |
| EBITDA Ratio | -105.28% | 434.27% | -44.12% | 31.36% | -340.35% | -213.54% | -118.58% | 17.12% | 20.27% | -618.02% | 0.00% | -1,559.07% | 0.00% | -536.27% | -4,903.10% |
| Operating Income | -228.71M | 1.67B | -1.08B | 44.30M | -1.67B | -553.65M | -78.88M | -15.22M | -2.75M | -7.74M | -931.66K | -64.61K | -21.39K | -19.58K | -26.92K |
| Operating Income Ratio | -76.97% | 413.30% | -208.08% | 8.10% | -418.53% | -244.61% | -101.19% | -38.14% | -21.65% | -675.34% | 0.00% | -1,559.07% | 0.00% | -436.27% | -4,903.10% |
| Total Other Income/Expenses | -242.64M | -455.64M | 750.94M | -440.51M | 159.91M | -59.71M | 68.53M | 3.81M | -621.00K | -912.37K | -1.27K | 0.00 | 0.00 | 0.00 | 26.92K |
| Income Before Tax | -471.36M | -3.31B | -329.43M | -1.68B | -1.51B | -657.78M | -52.54M | -17.06M | -3.37M | -8.93M | -932.93K | -64.61K | -21.39K | 0.00 | 0.00 |
| Income Before Tax Ratio | -158.63% | -822.61% | -63.31% | -308.05% | -378.43% | -290.61% | -67.41% | -42.76% | -26.54% | -779.58% | 0.00% | -1,559.07% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 12.33M | -4.77M | -8.95M | -13.14M | -121.61M | 12.32M | 1.59M | -401.00K | 126.00K | 1.42M | 2.75K | 0.00 | -4.76K | -4.49K | 26.92K |
| Net Income | -657.27M | -3.31B | -320.49M | -1.67B | -1.39B | -670.09M | -54.13M | -16.61M | -3.50M | -8.93M | -932.93K | -64.61K | -21.39K | -24.07K | -26.92K |
| Net Income Ratio | -221.19% | -821.42% | -61.59% | -305.65% | -347.93% | -296.06% | -69.45% | -41.63% | -27.53% | -779.58% | 0.00% | -1,559.07% | 0.00% | -536.27% | -4,903.10% |
| EPS | -6.47 | -71.37 | -8.19 | -44.96 | -39.86 | -1.99 | -0.31 | -0.14 | -0.05 | -0.30 | -15.77 | -0.06 | -0.02 | -0.02 | -0.08 |
| EPS Diluted | -8.79 | -71.37 | -8.19 | -44.96 | -39.86 | -1.99 | -0.31 | -0.14 | -0.05 | -0.30 | -15.77 | -0.06 | -0.02 | -0.02 | -0.08 |
| Weighted Avg Shares Out | 101.63M | 46.37M | 39.13M | 37.17M | 34.80M | 337.51M | 177.30M | 118.99M | 77.02M | 29.95M | 59.16K | 1.00M | 1.00M | 1.00M | 320.24K |
| Weighted Avg Shares Out (Dil) | 74.79M | 46.37M | 39.13M | 37.17M | 34.80M | 337.51M | 177.30M | 118.99M | 77.02M | 29.95M | 59.16K | 1.00M | 1.00M | 1.00M | 320.24K |
Canadian Gold Corp. Clarification to News Improperly Disseminated by Third Party Wire Services
Toronto, Ontario--(Newsfile Corp. - November 19, 2024) - Recently, and on more than one occasion, news releases pertaining to other public companies unrelated to Canadian Gold Corp. (TSXV: CGC) ("Canadian Gold" or the "Company"), have appeared as having been disseminated...
Canadian Gold Corp. Phase 3 Drilling at Tartan Mine Returns Multiple High-Grade Intercepts over Good Widths Extending Main Zone to the West Well Below Resource; Potential to Expand Resource Remains Excellent
Toronto, Ontario--(Newsfile Corp. - November 14, 2024) - Canadian Gold Corp. (TSXV: CGC) ("Canadian Gold" or the "Company") is pleased to announce results from its Phase 3 Drill Program at the Tartan Mine, located near Flin Flon, Manitoba. Results in...
Canopy Growth Corporation (CGC) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Canopy Growth (CGC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Canopy Growth Corporation (CGC) Q2 2025 Earnings Call Transcript
Canopy Growth Corporation (CGC) Q2 2025 Earnings Call Transcript
Canopy Growth Corporation (CGC) Reports Q2 Loss, Misses Revenue Estimates
Canopy Growth Corporation (CGC) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $1.80 per share a year ago.
Canopy Growth Reports Second Quarter Fiscal Year 2025 Financial Results
Storz & Bickel net revenue increased 32% year-over-year in Q2 FY2025 Continued growth across medical cannabis businesses, with net revenue increasing year-over-year by 16% in Canada and 12% in international markets Further improved balance sheet with early prepayment reducing senior...
Cannabis stocks plunge after DeSantis, Griffin win Florida fight against weed legalization
Amendment 3 – which would have legalized the recreational use of marijuana in the state's constitution – failed to receive the 60% support needed to pass under Florida law.
Cannabis stocks tank as Florida votes against recreational marijuana
Shares in cannabis stocks such as Trulieve Cannabis Corp. (CSE:TRUL), Curaleaf Hldgs Inc. (CSE:CURA, OTCQX:CURLF) and Verano Holdings Corp (CSE:VRNO, OTCQX:VRNOF) tanked after Florida rejected legalization of recreational marijuana. A ballot measure, known as Amendment 3, which would have allowed adults to possess up...
Top Canadian Cannabis Stocks to Track as U.S. Legalization Heats Up
As the election approaches, Canadian cannabis stocks are capturing attention, especially with potential U.S. legalization developments on the horizon. The U.S. cannabis industry is booming, with projected growth reaching $41 billion by 2025. This massive market is appealing to Canadian...
Investors Heavily Search Canopy Growth Corporation (CGC): Here is What You Need to Know
Zacks.com users have recently been watching Canopy Growth (CGC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Source: https://incomestatements.info
Category: Stock Reports